Abstract
Octreotide in Palliative Treatment of Hepatic Metastases: Is it Effective for Clinical Stabilization?
Highlights
Somatostatin has been shown to possess antimitotic activity against non-endocrine tumours, while octreotide, a somatostatin analogue, has shown considerable antitumor activity on animal models of various hepatic tumors
Kapadia commenting on the improvement of quality of life after the administration of octreotide in patients with hepatocellular carcinoma, reported that the possible mechanism of this, should be the diminishing of the effects of various humoral agents and/or cytokines released from the tumor.[10]
The possible role of octreotide in palliative treatment of symptomatic liver metastases from non-neuroendocrine primary carcinomas remains controversial in the literature
Summary
Somatostatin has been shown to possess antimitotic activity against non-endocrine tumours, while octreotide, a somatostatin analogue, has shown considerable antitumor activity on animal models of various hepatic tumors. We report on seven patients, (3 females, 4 males), age: (63, 70, 71, 75, 72, 80, 81 years-old), with symptomatic liver metastases from different primary tumors -two from unknown primary origin, four from primary pancreatic carcinoma (two in the head and two in the tail of the pancreas) and one from duodenal carcinoid tumor-, who were palliatively treated by long acting octreotide IM (octreotide LAR) monthly, according to schema published previously.[2] All patients complained for general symptoms attributed to hepatic metastases, including right upper abdominal pain, loss of appetite, malaise and weight loss.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
